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Available online 18 September 2014AbstractAim: Although statins have been proved to have cardioprotective effects, it remains to be investigated whether “statin-induced preconditioning
(PC)” can reduce the infarct size for senile animals.
Methods: Senile Wistar rats (weighing 350e450 g) were randomly assigned to one of 14 experiment groups (n  5 for each group). All hearts
underwent 30 minutes of coronary artery occlusion and 2 hours of reperfusion (control procedure). Ischemic PC was elicited by three cycles of
5-minute occlusion and 5-minute reperfusion. Statin PC was performed by administering Mevalotin (1 mg/kg, the optimal dose being determined
by a doseeeffect study) 30 minutes prior to the control procedure. In addition, pretreatment with glibenclamide, 5-hydroxydecanoic acid,
chelerythrine, genistein, and NG-nitro-4-arginine methyl ester, or their combination, was also performed to test possible signaling mechanisms.
Results: Statin PC decreased the infarct size significantly compared with the control group (22 ± 4% vs. 53 ± 4%, p < 0.01). Pretreatment with
NG-nitro-4-arginine methyl ester completely blocked the effects of Mevalotin (infarct size: 48 ± 4% vs. 22 ± 4%, p < 0.01). The cardioprotective
effects of statin PC could be blunted by antagonism of mitochondrial adenosine triphosphate (ATP)-sensitive potassium and sarcolemmal
ATP-sensitive potassium channels (glibenclamide: 50 ± 4% vs. 22 ± 4%, p < 0.01; 5-hydroxydecanoic acid: 50 ± 4% vs. 22 ± 4%, p < 0.01). In
addition, protein kinase C antagonist (chelerythrine) and tyrosine kinase antagonist (genisteine) also have similar effects (chelerythrine: 48 ± 4%
vs. 22 ± 4%, p < 0.01; genistein: 45 ± 4% vs. 22 ± 4%, p < 0.01).
Conclusion: It is established in this study the myocardial PC caused by statins, that is involved cellular mechanisms including mainly the
pathway of endothelial nitrous oxide synthase (eNOS)enitrous oxide donationeATP-sensitive potassium channels. Protein kinase C and tyrosine
kinase have regulatory effects.
Copyright © 2014, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Keywords: endothelial nitrous oxide synthase; mitochondrial adenosine triphosphate-sensitive potassium; preconditioning; statins1. Introduction
Preconditioning (PC) involves a pretreatment or pre-
maneuver that is able to decrease myocardial damage after a
severe decrease in coronary flow. We have demonstrated many
modes of PC in previous experiments to show cardioprotective
effects.1e3 The term “preconditioning” means a powerful* Department of Emergency Medicine, Shin-Kong Wu Ho-Su Memorial
Hospital, 95 Wen Chang Road, Taipei, Taiwan.
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2211-5587/Copyright © 2014, Taiwan Society of Emergency Medicine. Publishedexperimental tool that can reduce the infarct size (IS) after
ischemiaereperfusion or other pretreatments such as adren-
ergic stimulation,4 activation of adenosine receptors5 and
adenosine triphosphate (ATP)-sensitive potassium (KATP)
channels,6 and induction of heat shock proteins7 and oxidative
stress.8 Some investigators have further studied the possible
effector cells of such PC. Besides neutrophils, which we
earlier proposed to be affected by PC,1 endothelial cells are the
main target cells at present.2,9e11
Activation of G protein-linked phospholipase C, tyrosine
kinase pathways, and protein kinase C, and generation ofby Elsevier Taiwan LLC. All rights reserved.
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KATP channels are considered the most possible triggers and
effectors of PC.12 Recent studies suggested that mitochondrial
KATP channels (MitoKATP channels), in addition to sarco-
lemmal KATP channels, might account mainly for the protec-
tive mechanism.12e16 MitoKATP channel opening has been
proved to be related to mitochondrial swelling and optimiza-
tion of respiration,13 prevention of mitochondrial calcium
overload,14 and control of reactive oxygen radicals,15,16 all of
which are possibly linked to cardioprotection during severe
myocardial ischemia and infarction.
As mentioned above, cellular targets of PC seem to be
heterogeneous. Although saline-perfused isolated hearts or
isolated cardiomyocytes can be preconditioned,17,18 the so-
called microvascular component of PC has been pre-
sented.19e21 The concept is concerned with the reduction of
postischemic inflammation or mitigation of leukocyte adhe-
sion in the perfused vascular bed after PC. Endothelial cells,
the interface between parenchymal tissue and blood cells, are
involved in the significant pathophysiological process.
On the other hand, statins (3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors) have been available for
decades. Some clinical trials have indicated that statins appear
to have beneficial effects independent of their cholesterol-
lowering properties, when compared with other agents.
These so-called pleiotropic properties include anti-
inflammatory effects, plaque stabilization,22e24 improved
endothelial function, and inhibition of vascular smooth muscle
cell proliferation.25 The beneficial pleiotropic effects of statins
in protecting the isolated murine hearts against lethal reper-
fusion injury via activation of phosphatidylinositide 3-kinases
(PI3K)/Akt prosurvival signaling pathway and its downstream
effectors, endothelial nitrous oxide synthase (eNOS), were
also demonstrated.26 In addition, phosphorylation of multiple
prosurvival pathways involving p44/p42 Mitogen-activated
protein kinases (MAPK), p38 MAPK, and heat shock protein
(HSP) 27 were also demonstrated in a later study.27
It is well known that statins are associated with nitrous
oxide synthase (NOS) activation. Nitrous oxide (NO) is a
unique intra/intercellular messenger involved in the regulation
of many physiological functions.28 Any compounds that
modulate NO release may display a great therapeutic value.29
Different statins such as lovastatin, atorvastatin, pravastatin,
and simvastatin demonstrate variable potency to enhance the
NO/oxygen concentration ratio by enhancing NOS, resulting
in increased endothelial NO activities.30
In addition, acutely administered statins minimize the
damaging effect of transient cerebral31 or myocardial
ischemia32 in animal models. Many studies31e33 clearly indi-
cate the role of NOS activated by statins. In addition, some
other statins have been proved to attenuate oxidant-induced
mitochondrial dysfunction in cardiac myocytes.34 Clinical ob-
servations also demonstrated significant protection from myo-
necrosis among patients undergoing atherectomy with statins.35
We designed the following in vivo study to investigate the
presence of the phenomenon “statin-induced PC” and its
cellular mechanisms.2. Methods2.1. Animal preparationMale Wistar rats, weighing 350e450 g and fed a standard
diet, were included in this study. After induction of anesthesia
with intraperitoneal pentobarbitone (50 mg/kg body weight),
all the animals were ventilated with room air via endotracheal
intubation and a rodent respirator (Harvard Apparatus, Boston,
MA, USA) at 60e70 breaths per minute. The right carotid
artery was cannulated to measure the mean blood pressure and
heart rate via a Could PE-50 pressure transducer, which was
connected to a Grass polygraph (Grass Technologies, RI.
USA). The right jugular vein was cannulated to infuse saline
or drugs. A left thoracotomy was performed to expose the
heart at the fifth intercostal space. After removing the peri-
cardium, a 6-0-Prolene ligation, together with a snare
occluder, was placed over the origin of the left anterior
descending artery. Regional ischemia was achieved by pulling
the snare and securing the threads with a mosquito hemostat,
which indicated that approximately 60% of the myocardium
was ischemic in our study.2.2. Experimental protocolsThe rats included in the present study were randomly
assigned to one of the experimental groups (n  5 for each
group). All hearts underwent 30 minutes of coronary artery
occlusion and 2 hours of reperfusion (control procedure) after
an initial 30-minute stabilization period. Ischemic PC was eli-
cited by three cycles of 5-minute occlusion and 5-minute
reperfusion. Statin PC was performed by administering the
drugMevalotin (1 mg/kg, the optimal dose being determined by
a doseeeffect study) 30 minutes prior to the control procedure.
Glibenclamide (2 mg/kg), a sarcolemmal KATP channel antag-
onist, was administered 30minutes prior to statin PC to examine
the role of the channel. The effect of 5-hydroxydecanoic acid
(5-HD), a MitoKATP channel-selective antagonist, was also
examined by giving 10 mg/kg 5-HD 5minutes prior to the statin
PC. To evaluate the possible roles of protein kinase C and
tyrosine kinase, their antagonists, chelerythrine (2 mg/kg, 30
minutes prior to statin PC) and genistein (5 mg/kg, 5 minutes
prior to statin PC), or their combination for synergic effects,
were also given as a pretreatment in various groups. To test the
role of NOS in statin-induced cardioprotection, we also deter-
mined the effects of the NOS inhibitor NG-nitro-4-arginine
methyl ester (L-NAME). L-NAME (50 mg/kg) was adminis-
tered 30 minutes prior to ischemic PC with or without statin
pretreatment, and also prior to statin PC.
In summary, the rats were assigned to the following groups
for carrying out the experiments:
1. Control group: 30-minute occlusion þ 2-hour reperfu-
sion (control procedure)
2. Ischemic PC: (5-minute occlusion þ 5-minute
reperfusion)  3 þ control procedure
3. Statin PC: Mevalotin 30 minutes þ control procedure
129T.-L. Wang / Journal of Acute Medicine 4 (2014) 127e1324. L-NAME þ ischemic PC: L-NAME þ (5-minute
occlusion þ 5-minute reperfusion)  3 þ control
procedure
5. L-NAME þ statin PC: L-NAME þ Mevalotin 30
minutes þ control procedure
6. Glibenclamide þ ischemic PC: glibenclamide þ (5-
minute occlusion þ 5-minute reperfusion)  3
þ control procedure
7. Glibenclamide þ statin PC: glibenclamide þ Mevalotin
30 minutes þ control procedure
8. 5-HD þ ischemic PC: 5-HD þ (5-minute
occlusion þ 5-minute reperfusion)  3 þ control
procedure
9. 5-HD þ statin PC: 5-HD þ Mevalotin 30
minutes þ control procedure
10. Chelerythrineþ ischemic PC: chelerythrineþ (5-minute
occlusion þ 5-minute reperfusion)  3 þ control
procedure
11. Chelerythrine þ statin PC: chelerythrine þ Mevalotin
30 minutes þ control procedure
12. Genistein þ ischemic PC: genistein þ (5-minute
occlusion þ 5-minute reperfusion)  3 þ control
procedure
13. Genistein þ statin PC: genistein þ Mevalotin 30
minutes þ control procedure
14. Sham group2.3. Determination of ISAs previously described,5 the IS and the area at risk of
ventricular myocardium were measured by planimetry after
incubation with 1% triphenyltetrazolium (Sigma Co., St
Louis, MO, USA) in phosphate buffer (pH 7.4) and 10%
formalin. The volume of the left ventricle, the infarct volume,
and the volume of the area at risk were then calculated by
multiplying each area by the slice thickness and summing the
products. The IS was expressed as a percentage of the area at
risk.2.4. Measurement of eNOS messenger RNA by reverse
transcriptase-polymerase chain reactionFig. 1. Infarct size/area at risk in various experiment groups (statin PC).
5-HD ¼ 5-hydroxydecanoic acid; L-NAME ¼ NG-nitro-4-arginine methyl
ester; PC ¼ preconditioning; SPC ¼ statin preconditioning.Myocardial tissue samples were obtained from the rats
injected with Mevalotin (~1 mg/kg) or saline vehicle and
rapidly frozen in liquid nitrogen. Total RNA was extracted
from mouse heart, and reverse transcriptase-polymerase chain
reaction (RT-PCR) was performed as described previously.35
The mouse eNOS fragment was amplified using the sense
primer (50-GCAGAAGAGTCCAGCGAACA-30)36 and the
antisense primer (50-GGCAGCCAAACACCAAAGTC-30).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as the internal control. The mouse GAPDH fragment was
amplified using the sense primer (50-CGGAGTCAACG
GATTTGGTCGTAT-30) and the antisense primer (50-AGCCT
TCTCCATGGTGGTGAAGAC-30). The expression of eNOS
messenger RNA (mRNA) was normalized to the level of
GAPDH mRNA in each experiment.2.5. ChemicalsAll chemicals were purchased from Sigma Co. except those
that were particularly mentioned. Mevalotin was obtained
from the Laboratory of Sankyo Co., Inc. (Tokyo, Japan).
Mevalotin was injected intraperitoneally as a single dose of
1 mg/kg prior to the corresponding experiments.2.6. Statistical analysisAll values are expressed as mean ± the standard error of the
mean. Analysis of variance, using NewmaneKeuls post hoc
test, was used to determine whether any significant differences
existed among groups with regard to the IS and area at risk. A
value of p < 0.05 was considered to be statistically significant.
3. Results3.1. Cardioprotection from statin PCWe determined the decrease of the IS after statin PC using
the triphenyltetrazolium method, as described above. Pre-
treatment with statin reduces the IS significantly (Fig. 1;
22 ± 4% vs. 53 ± 4%, p < 0.01). The cardioprotective effect
provided by statin PC is comparable to that provided by
ischemic PC (Fig. 1; 24 ± 4% vs. 53 ± 4%, p < 0.01).3.2. Mechanisms of statin PCTo investigate the cellular mechanisms of statin PC, we
applied various agents prior to statin PC. The main results are
depicted in Figs. 1 and 2. Pretreatment with L-NAME
completely blocked the effects of IS reduction provided by
statin PC (Fig. 1; 48 ± 4% vs. 22 ± 4%, p < 0.01). Both
MitoKATP and sarcolemmal KATP channels can antagonize the
cardioprotective effects of statin PC (Fig. 1; glibenclamide:
50 ± 4% vs. 22 ± 4%, p < 0.01; 5-HD: 50 ± 4% vs. 22 ± 4%,
p < 0.01). In addition, protein kinase C antagonist (cheler-
ythrine) and tyrosine kinase antagonist (genistein) also have
Fig. 2. Infarct size/area at risk in various experiment groups (ischemic PC). 5-
HD ¼ 5-hydroxydecanoic acid; IPC ¼ ischemic preconditioning; L-
NAME ¼ NG-nitro-4-arginine methyl ester; PC ¼ preconditioning.
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p < 0.01; genisteine: 45 ± 4% vs. 22 ± 4%, p < 0.01).
On comparison with Fig. 2, we found that the cellular
mechanisms of statin PC are similar to those of ischemic PC.
These observations imply that the donation of NO to the
downstream KATP channels remains the key pathway involved
in myocardial PC.3.3. Cardiomyocyte eNOS activation by statin PCActivation of myocardial eNOS activation was observed in
the myocardium treated with statin PC (1.60 ± 0.2-fold vs.
control, p < 0.05). L-NAME can block the statin-induced
eNOS mRNA expression completely. However, antagonism
of sarcolemmal KATP channels, tyrosine kinase C, MitoKATP
channels, and protein kinase C all restore and even enhance
the activation of eNOS mRNA (see Fig. 3). These results may
imply that eNOSeNO donationeMitoKATP form a positive
feedback.
To prove these points, we investigated the eNOS mRNA
expression by RT-PCR. Surprisingly, the results were almostFig. 3. Expression of eNOS mRNA by RT-PCR. 5-HD ¼ 5-hydroxydecanoic
acid; eNOS ¼ endothelial nitrous oxide synthase; L-NAME ¼ NG-nitro-4-
arginine methyl ester; PC ¼ preconditioning; RT-PCR ¼ reverse
transcriptase-polymerase chain reaction; SPC ¼ statin preconditioning.the same as those observed in the case of statin PC. Activation
of myocardial eNOS was observed in the myocardium treated
with ischemic PC (1.57 ± 0.2-fold vs. control, p < 0.05).
L-NAME can block the statin-induced eNOS mRNA expres-
sion completely. Antagonism of sarcolemmal KATP channels,
tyrosine kinase C, MitoKATP channels, and protein kinase C
restores and even enhances the activation of eNOS mRNA.
These results may further confirm that there is a positive
feedback in eNOSeNO donationeMitoKATP channels.
4. Discussion
This study demonstrated that preadministration of statin can
provoke cardioprotective effects and reduce the IS in a rat
myocardial infarction model. Cardioprotective effects are, at
least partially, related to the activation of the myocardial eNOS
system and KATP channels, which are modified by an additional
signaling pathway such as the tyrosine kinase and protein kinase
C system. There are positive feedbacks between the tyrosine
kinase/protein kinase C system and eNOSeNOeMitoKATP
channels.
Statins are well known to be associated with NOS activa-
tion. NO is a unique intra/intercellular messenger involved in
the regulation of many physiological functions such as central
and peripheral neurotransmission, smooth muscle contractility,
platelet reactivity, and angiogenesis, among others.28 Inap-
propriate production of NO has been linked to a number of
pathologies; therefore, compounds that modulate its release
may display a great therapeutic value.29 NO is generated by a
family of enzymes known as NOS, named after the tissues in
which they were originally described. However, eNOS and
neuronal NOS are constitutively expressed not only in endo-
thelia and neurons, but also in many other cell types.30 They
release NO in response to receptor stimulation after activation
of the Ca2þ/calmodulin-dependent pathway.37 More recently,
different kinds of stimuli have been proved to activate eNOS
in a Ca2þecalmodulin-independent way. It has been reported
that basic fibroblast growth factor (FGF), similar to what was
reported for bradykinin,38 is able to activate eNOS in Chinese
hamster ovary-k1 cells, via the sphingomyelinase-dependent
generation of ceramide, causing translocation of eNOS from
the plasma membrane, where it is bound to caveolin-1, to the
cytosol in its active form.39 Among the different roles attrib-
uted to NO in physiology and pathology, its involvement in
carcinogenesis and angiogenesis has achieved great impor-
tance recently.40e42 NO has been reported to induce vascular
endothelial growth factor expression in carcinoma cells43 and
neovascularization in tumors.44 Moreover, angiogenic factors,
including both basic FGF and vascular endothelial growth
factor, are powerful NOS activators.39,41 Thus, identification
of compounds with antiangiogenic properties is of pivotal
relevance for the inhibition of tumor growth, and substances
able to block NO production may be active in this respect. The
tested statins, i.e., lovastatin, atorvastatin, pravastatin, and
simvastatin, demonstrate variable potency to enhance the NO/
oxygen concentration ratio after stimulation of NOS, resulting
in an increase of NO bioavailability in endothelial cells.37
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minimize the deteriorating effect of transient cerebral or
myocardial ischemia in animal models.31,32 These and other
studies elucidate a role for NOS activated by statins.33 IN
addition, some statins have been proved to attenuate oxidant-
induced mitochondrial dysfunction in cardiac myocytes.34,35
These basic studies supported the clinical observation that
statins have certain cardioprotective effects. For example, the
incidence of myonecrosis in patients undergoing rotational
atherectomy was evaluated by preprocedural statin use. The
incidence of any myonecrosis or significant myonecrosis was
significantly lower among patients pretreated with statins. This
difference remained significant after multivariable and pro-
pensity adjustment.35
Our study has certain limitations. The first is that there is a
doseeeffect relationship between the glibenclamide dose and
its effect on ischemic PC and statin PC, as evident from our
data. As mentioned previously, the doses of glibenclamide that
completely blocked PC varied widely.3,12,45e48 The differ-
ences may arise from the use of different animals for various
experiments. In most of the previous studies the Langendorff
isolated heart preparation was utilized, whereas we used intact
animals. In vivo pharmacokinetics may be complicated and
even individualized. However, we believe that such a model
can mimic actual pathophysiological conditions in clinical
settings.
The second limitation is that we cannot demonstrate
whether the cellular mechanisms of statin PC are different
among animals of different age groups. The results of this
study are similar to those of previous studies in which younger
animals were used for experiments. Further study designs
comparing the degree of cardioprotective effects of statin and
the differences in possibly involving signaling pathways may
be needed.
In this study, we have focused upon the acute car-
dioprotective effects of statin PC. It remains to be answered
whether such protective effects persist or whether delayed statin
PC can occur.
In summary, Mevalotin, similar to other statins, has been
proved to provide cardioprotective effects mimicking ischemic
PC. Activated myocardial eNOS system and KATP channels
are the main signaling pathways.
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